This plain language summary describes a study that looked at the different tests used to detect a rare type of cancer called TRK (tropomyosin receptor kinase) fusion cancer in people taking part in three clinical trials testing the medication larotrectinib.
Read the full article here.
The original article on which this plain language summary is based is titled ‘Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib’ and was published in Cancer Genetics. Read the original article here.